

Special Issue

Immune Inhibitory Mechanisms and New Insights into Ovarian Cancer Treatment

Message from the Guest Editors

The latest advances in the field of tumor immunology and immunotherapy emphasize that ovarian cancer cells can evade the host's immune response and stimulate tumor development by deactivation or death of crucial immune system effector cells, i.e., T cells and NK cells. One of the negative regulators of activated T cells are immune checkpoint inhibitors (ICPs), e.g., programmed cell-death receptor 1 (PD-1) and its ligands (PD-L1, PD-L2), T-cell immunoglobulin, and ITIM domain (TIGIT) and T-cell immunoglobulin-3 (TIM-3) and its ligand galectin 9 (Gal-9) axis. The co-expression status of ICPs on T cells in the OC TME is pivotal to understanding the complex immune-inhibitory mechanism. The synergistic model of action of these immune factors may be a promising target in ovarian cancer treatment. This Special Issue of *Biomedicines* will present research articles and reviews exploring mechanisms of ovarian cancer escaping from immune surveillance, tissue invasion, and metastasis, and current as well as novel immune-modulating/inhibiting strategies in the treatment of OC. All scientists working in these fields are cordially invited to submit their manuscripts.

Guest Editors

Prof. Dr. Iwona Wertel

Independent Laboratory of Cancer Diagnostics and Immunology, Department of Oncological Gynaecology and Gynaecology, Faculty of Medicine, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland

Dr. Agnieszka Bojarska-Junak

Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/121480

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).